ArticleFrontiers in immunology2026
Association between neutrophil percentage-to-albumin ratio and adverse clinical outcomes after successful percutaneous coronary intervention for chronic total occlusion: a cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has improved outcomes, yet residual cardiovascular risk persists. The neutrophil percentage-to-albumin ratio (NPAR), an integrated marker of inflammation and nutritional status, has not been examined in successfully revascularized CTO patients. We investigated whether NPAR is independently associated with long-term adverse outcomes in this population. Methods: This single-center retrospective cohort study included 1513 consecutive patients who underwent successful CTO PCI. NPAR was calculated as (neutrophil percentage × 100)/albumin (g/dL). The primary endpoint was all-cause mortality, secondary endpoints were cardiovascular mortality and cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). Multivariable Cox regression and restricted cubic splines (RCS) assessed the association between NPAR and clinical outcomes. Time-dependent Receiver operating characteristics (ROC) curves were used to evaluate the ability for NPAR to predict all-cause mortality. Results: During a median follow-up of 810 days, 83 (5.5%) all-cause deaths, 53 (3.5%) cardiovascular deaths, and 73 (4.8%) cardiovascular events occurred. After multivariable adjustment, each 1-standard deviation increase in NPAR was associated with a 50% higher risk of all-cause mortality (HR 1.50, 95% CI 1.23-1.83, P<0.001), a 59% higher risk of cardiovascular mortality (HR 1.59, 95% CI 1.23-2.05, P<0.001), and a 42% higher risk of cardiovascular events (HR 1.42, 95% CI 1.13-1.79, P = 0.003). RCS analysis revealed a linear association between NPAR and all-cause mortality (P for non-linearity = 0.971), cardiovascular mortality (P for non-linearity = 0.150), and major cardiovascular events (P for non-linearity = 0.152). Time-dependent ROC analyses demonstrated that adding NPAR to a basic model comprising age, multi-vessel disease, and LVEF significantly improved discrimination for all-cause mortality at 1, 2, and 3 years (ΔAUC 0.092, 0.076, and 0.058, respectively; all P < 0.0001). The optimal NPAR cut-off values derived from the maximum Youden index were stable across all three time points (15.71, 16.18, and 15.37, respectively), yielding sensitivities of 71.8% to 72.6% and specificities of 73.2% to 75.7%. Conclusion: In patients undergoing successful CTO PCI, elevated NPAR is independently and linearly associated with increased long-term mortality and major cardiovascular events. This simple, objective biomarker may refine post-intervention risk stratification and identify high-risk individuals warranting intensified secondary prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.